RNAC is tracked by BiotechSign with a current catalyst score of 73/100 and grade B. The page summarizes 156 active signals, including 0 PDUFA, 1 insider buying, and 1 clinical trial signals, with data refreshed on 2026-07-19.
As of 2026-07-19, Cartesian Therapeutics, Inc. (RNAC) has a BiotechSign Catalyst Score of 73/100, rated B. The company has 156 active signals tracked by BiotechSign and 1 clinical trial signal. There is 1 insider buying signal on file. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.
This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).
Cartesian Therapeutics, Inc. Common Stock (RNAC) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.
RNAC has 3 Form 4 insider filings recorded at the SEC in the past 30 days[1].